Hutchmed (China) (HCM) said late Wednesday that the China National Medical Products Administration has accepted and granted priority review to its New Drug Application for the combination of Orpathys and Tagrisso for the treatment of patients with a specific type of non-small cell lung cancer.
The company said this acceptance also triggers a milestone payment from AstraZeneca (AZN), which is leading the development of Orpathys outside China.
The decision was supported by data from a late-stage trial that evaluated the efficacy and safety of a combination of the two drugs in comparison to chemotherapy and met its primary endpoint of progression-free survival in an interim analysis.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。